Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB    UNC   BE0003739530

UCB (UNC)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
11/15/2017 11/16/2017 11/17/2017 11/20/2017 11/21/2017 Date
60.35(c) 60.72(c) 62.758(c) 61.165(c) 62.113 Last
973 0 0 0 0 Volume
-0.90% +0.61% +3.36% -2.54% +1.55% Change
More quotes
Financials (€)
Sales 2017 4 347 M
EBIT 2017 996 M
Net income 2017 629 M
Debt 2017 611 M
Yield 2017 1,95%
Sales 2018 4 506 M
EBIT 2018 1 100 M
Net income 2018 725 M
Debt 2018 81,7 M
Yield 2018 2,05%
P/E ratio 2017 17,63
P/E ratio 2018 15,44
EV / Sales2017 2,92x
EV / Sales2018 2,70x
Capitalization 12 067 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.The company was founded by Emmanuel Janssen on January 18, 1928 and is... 
Sector
Pharmaceuticals
Calendar
11/23Presentation
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
11/14 UCB : New study data shows prior osteoporotic fractures put women at increased r..
11/10 DERMIRA : and UCB Agree to End Collaboration Agreement for CIMZIA
11/06 UCB : Dermira and UCB Agree to End Collaboration Agreement for CIMZIA …
10/20 UCB FIRST NINE MONTHS INTERIM REPORT :  Strong 9 …
10/20 UCB : By the time you finish reading this headline another person …
10/17UCB SA : quaterly earnings release
10/17 UCB : Transparency notification The Capital Group Companies
10/13 UCB : Transparency notification The Capital Group Companies
09/21 UCB : Studies from UCB S.A. Reveal New Findings on Extracellular Space (Quantita..
09/15 NEW INDICATION FOR BRIVIACT® (BRIVAR : UCB’s newest antiepileptic drug &he..
More news
Sector news : Pharmaceuticals - NEC
06:36a Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimizes likely staff losses
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimises likely staff losses
11/20 FTSE recoups early losses as cyclicals recover
11/20DJSHIRE : Appoints Thomas Dittrich as Chief Financial Officer
More sector news : Pharmaceuticals - NEC
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 17
Average target price 65,8 €
Spread / Average Target 6,1%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB2.26%14 167
JOHNSON & JOHNSON19.78%370 552
NOVARTIS11.20%220 012
ROCHE HOLDING LTD.-1.55%212 913
PFIZER8.90%210 711
MERCK AND COMPANY-6.23%147 550